Researchers Studying Donor NK Cell Infusions in patients with High-Risk AML Undergoing a HaploHCT
Phase: Recruiting
First Posted: February
Condition(s): Acute Myeloid Leukemia (AML)
NCT Number: NCT04836390 Other Study ID Number(s): EXCEL
What Is the Purpose of This Study?
To test the safety and effectiveness of a new treatment of infusing natural killer (NK) cells into the patient’s body to help fight AML.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Have high-risk acute myeloid leukemia (AML).
- Are under 25 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04836390
What Will Happen During This Study?
- Participants will receive three infusions of special cells called HaploNK cells. The first infusion will be given one day before the transplant, the second seven days after the transplant, and the third between 42 and 90 days after the transplant.
- Transplant will consist of a busulfan and cyclophosphamide-based conditioning regimen and post-transplant cyclophosphamide to help prevent graft versus host disease.
Principal Investigator
Discover More Research
Explore additional studies relating to cell therapyYour Might Also Be Interested In
Research and Clinical Care: How They Work Together to Treat Children
In this 700 Children's blog post for parents, Nationwide Children's highlights how clinical research and clinical care work together as a key part of our strategic plan to achieve the best outcomes for children. Before delving into these elements work together, the post covers the basics of clinical research.
Leukemia (ALL and AML)
Leukemia (ALL and AML) is the most common form of childhood cancer. It affects the tissues of the body which make the blood cells and the bone marrow. When leukemia strikes, the body makes an abundance of abnormal white cells that invade the marrow and crowd out the normal healthy blood cells.